Literature DB >> 10623862

Myelin-associated oligodendrocytic basic protein: identification of an encephalitogenic epitope and association with multiple sclerosis.

A Holz1, B Bielekova, R Martin, M B Oldstone.   

Abstract

Myelin-associated oligodendrocytic basic protein (MOBP) is an abundant myelin constituent expressed exclusively by oligodendrocytes, the myelin-forming cells of the CNS. We report that MOBP causes experimental allergic encephalomyelitis and is associated with multiple sclerosis. First, we note that purified recombinant MOBP inoculated into SJL/J mice produces CNS disease. Tests of overlapping peptides spanning the murine MOBP molecule map the encephalitogenic site to amino acids 37-60. MOBP-induced experimental allergic encephalomyelitis shows a severe clinical course and is characterized by a prominent CD4+ T lymphocyte infiltration and a lesser presence of CD8+ T cells and microglia/macrophages around vessels and in the white matter of the CNS. Second, PBL obtained from patients with relapsing/remitting multiple sclerosis mount a proliferative response to human MOBP, especially at amino acids 21-39. This response equals or exceeds the response to myelin basic protein and an influenza virus hemagglutinin peptide, both serving as internal controls. Thus, a novel myelin Ag, MOBP aa 37-60, plays a role in rodent autoimmune CNS disease, and its human MOBP counterpart is associated with the human demyelinating disease multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10623862     DOI: 10.4049/jimmunol.164.2.1103

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis.

Authors:  Sushmita Sinha; Michael P Crawford; Sterling B Ortega; Nitin J Karandikar
Journal:  J Mult Scler (Foster City)       Date:  2015-01

Review 3.  IL-17 producing T cells in mouse models of multiple sclerosis and rheumatoid arthritis.

Authors:  Bernadette Pöllinger
Journal:  J Mol Med (Berl)       Date:  2012-01-10       Impact factor: 4.599

4.  A new approach for evaluating antigen-specific T cell responses to myelin antigens during the course of multiple sclerosis.

Authors:  Nathalie Arbour; Andreas Holz; Jack C Sipe; Denise Naniche; John S Romine; Jack Zyroff; Michael B A Oldstone
Journal:  J Neuroimmunol       Date:  2003-04       Impact factor: 3.478

Review 5.  Spectrum and classification of inflammatory demyelinating diseases of the central nervous system.

Authors:  B Kalman; F D Lublin
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 6.  The mechanisms and applications of T cell vaccination for autoimmune diseases: a comprehensive review.

Authors:  Xin Huang; Haijing Wu; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

7.  Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides.

Authors:  C Arturo Solares; Andrea E Edling; Justin M Johnson; Moo-Jin Baek; Keiko Hirose; Gordon B Hughes; Vincent K Tuohy
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

8.  Multiantigen/multiepitope-directed immune-specific suppression of "complex autoimmune encephalomyelitis" by a novel protein product of a synthetic gene.

Authors:  Ming-Chao Zhong; Nicole Kerlero de Rosbo; Avraham Ben-Nun
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

9.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 10.  Immune tolerance to myelin proteins.

Authors:  Audrey Seamons; Antoine Perchellet; Joan Goverman
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.